Search research articles
Contact Us
Filters
Showing results (161-170 of 231) with videos related to
Page
of 24
Sort By:
Annals of Surgical Oncology
|
March 12, 2026
ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study
Sherko Kuemmel, Peter A Fasching, Peter Schmid, et al.
Journal of the National Cancer Institute
|
May 23, 2018
Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
Michail Ignatiadis, Gert Van den Eynden, Salgado Roberto, et al.
NPJ Breast Cancer
|
October 2, 2025
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy
Javier Cortes, Oleg Lipatov, Seock-Ah Im, et al.
EMBO Molecular Medicine
|
March 27, 2025
Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity
Bo He, Kira H Wood, Zhi-Jie Li, et al.
Journal of the National Cancer Institute
|
March 4, 2025
Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates
Laura Pala, Federico Merlo, Isabella Sala, et al.
The New England Journal of Medicine
|
February 27, 2020
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid, Javier Cortes, Lajos Pusztai, et al.
Breast Cancer Research and Treatment
|
August 14, 2020
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1
Hope S Rugo, Veronique Dieras, Javier Cortes, et al.
The Lancet. Oncology
|
March 7, 2021
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P Winer, Oleg Lipatov, Seock-Ah Im, et al.
The New England Journal of Medicine
|
July 20, 2022
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Javier Cortes, Hope S Rugo, David W Cescon, et al.
The Lancet. Oncology
|
February 1, 2024
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations
Icro Meattini, Carlotta Becherini, Saverio Caini, et al.
Page
of 24
Search research articles
Search
Showing results (161-170 of 231) with videos related to
Sort By:
Page
of 24
Annals of Surgical Oncology
|
March 12, 2026
ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study
Sherko Kuemmel, Peter A Fasching, Peter Schmid, et al.
Journal of the National Cancer Institute
|
May 23, 2018
Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
Michail Ignatiadis, Gert Van den Eynden, Salgado Roberto, et al.
NPJ Breast Cancer
|
October 2, 2025
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy
Javier Cortes, Oleg Lipatov, Seock-Ah Im, et al.
EMBO Molecular Medicine
|
March 27, 2025
Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity
Bo He, Kira H Wood, Zhi-Jie Li, et al.
Journal of the National Cancer Institute
|
March 4, 2025
Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates
Laura Pala, Federico Merlo, Isabella Sala, et al.
The New England Journal of Medicine
|
February 27, 2020
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid, Javier Cortes, Lajos Pusztai, et al.
Breast Cancer Research and Treatment
|
August 14, 2020
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1
Hope S Rugo, Veronique Dieras, Javier Cortes, et al.
The Lancet. Oncology
|
March 7, 2021
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P Winer, Oleg Lipatov, Seock-Ah Im, et al.
The New England Journal of Medicine
|
July 20, 2022
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Javier Cortes, Hope S Rugo, David W Cescon, et al.
The Lancet. Oncology
|
February 1, 2024
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations
Icro Meattini, Carlotta Becherini, Saverio Caini, et al.
Page
of 24